Morbidity and Mortality in Gynecomastia - registry study - EDMARC

Go to content
Morbidity and Mortality in Males Diagnosed with Gynecomastia
January 2019 – December 2026
Gynecomastia is a benign proliferation of male glandular breast tissue, which occurs frequently among males. But the evidence on the long-term and general health of males with gynecomastia is entirely lacking.
Aims and Study Design
We aim to assess:
- health prior to and following a diagnosis of gynecomastia.
- Mortality rates following a diagnosis of gynecomastia
We will use Danish registries recognized for validity and completeness including:
- Central Population Registry
- National Patient Registry
- Cancer Registry
- Prescription Registry
- Causes of death Registry
We have created a cohort of 140,574 males diagnosed with incident gynecomastia (n=23,429) and age- and calendar-matched males with no gynecomastia (n=117,145) from the background population. Males with gynecomastia were stratified into males without (idiopathic) or with a pre-existing recognized risk factor (disease/medication).
Cox regression models will be used to investigate disease risk and mortality following gynecomastia.
Logistic regression models will be used to investigate disease prior gynecomastia diagnosis.

Publications from the study
Uldbjerg CS, Lim YH, Bräuner EV, Juul A. Increased Morbidity in Males Diagnosed With Gynecomastia: A Nationwide Register-based Cohort Study. J Clin Endocrinol Metab. 2023 Jun 16;108(7):e380-e387. doi: 10.1210/clinem/dgad048.
MDSc, Professor
Dept. of Growth and Reproduction
Copenhagen University Hospital, Rigshospitalet
Blegdamsvej 9
DK-2100 Copenhagen Denmark

Back to content